Skip to main content
TrimSoMoEverything GLP-1, in one place
FDA Regulatory Enforcement Record

Ezra Holdco LLC dba Ezra

Has Ezra received an FDA warning letter? Yes. FDA issued a warning letter dated June 8, 2026 concerning products containing semaglutide and tirzepatide.

Letter facts

Letter date
June 8, 2026 (2026-06-08)
Issuing office
Center for Drug Evaluation and Research (CDER)
Recipient type
Telehealth
Products named
compounded drug productssemaglutidetirzepatide
Violation categories
MisbrandingFalse or misleading claims

Understanding these violation categories

Misbranding

FDA says the products' labeling, promotion, or directions did not meet federal requirements, such as lacking adequate directions for use or making unsubstantiated claims. A warning letter is FDA's notice of what it believes are significant violations.

False or misleading claims

FDA says the company made claims regarding product equivalence, safety, or FDA approval that were inaccurate or not supported by evidence. A warning letter notifies the recipient to bring promotions into compliance.

Factual Violation Summary

FDA says the website offers compounded semaglutide and tirzepatide labeled "Ezra," falsely suggesting Ezra is the compounder, making the products misbranded under FD&C Act sections 502(a) and 502(bb).

Active Drug Ingredients

Statutory Citations & Specific Allegations

  • misbranding
  • false or misleading labeling
  • false or misleading advertising or promotion

More letters about Semaglutide

Recent FDA warning letters concerning Semaglutide:

Similar violations (Misbranding)

Recent warning letters with related regulatory findings:

Regulatory Compliance & Editorial Standard:

The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.

Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.